Novartis Suspends Cancer Drug Production in Italy, US
2022年5月6日 - 1:14AM
Dow Jones News
By Cecilia Butini
Novartis AG said it has suspended production of two of its
oncology drugs at sites in Italy and New Jersey, U.S., as a result
of potential quality issues in the manufacturing process.
The halt affects manufacture of gastroenteropancreatic
neuroendocrine tumor drug Lutathera and of prostate-cancer drug
Pluvicto, Novartis said, adding that the action affects commercial
and clinical-trial supply.
The Swiss pharma major expects to resolve the issues and resume
some supply within six weeks, pending confirmation via a continuing
review, it said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
May 05, 2022 11:59 ET (15:59 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
過去 株価チャート
から 3 2024 まで 4 2024
Novartis (NYSE:NVS)
過去 株価チャート
から 4 2023 まで 4 2024
